Copyright
©The Author(s) 2016.
World J Gastroenterol. Oct 28, 2016; 22(40): 8967-8977
Published online Oct 28, 2016. doi: 10.3748/wjg.v22.i40.8967
Published online Oct 28, 2016. doi: 10.3748/wjg.v22.i40.8967
Table 3 Summary of adverse effects (mean ± SD)
| Case | Creatinine at baseline (mg/dL) | eGFR at baseline (mL/min/1.73 m2) | Adverse effects (grade) | Onset time of grade 2 adverse effects |
| 1 | 1.19 | 45.6 | Elevated creatinine (3) | Week 2 |
| Anorexia (2) | Week 2 | |||
| 2 | 0.70 | 83.7 | Elevated creatinine (2) | Week 2 |
| Anorexia (2) | Week 3 | |||
| 3 | 1.00 | 56.9 | Elevated creatinine (2) | Week 3 |
| 4 | 0.75 | 80.2 | Elevated creatinine (2) | Week 3 |
| 5 | 0.63 | 70.2 | Elevated creatinine (2) | Week 4 |
| Anorexia (1) | ||||
| 6 | 0.43 | 111.5 | Anorexia (1) | |
| Elevated creatinine (1) |
- Citation: Saeki I, Yamamoto N, Yamasaki T, Takami T, Maeda M, Fujisawa K, Iwamoto T, Matsumoto T, Hidaka I, Ishikawa T, Uchida K, Tani K, Sakaida I. Effects of an oral iron chelator, deferasirox, on advanced hepatocellular carcinoma. World J Gastroenterol 2016; 22(40): 8967-8977
- URL: https://www.wjgnet.com/1007-9327/full/v22/i40/8967.htm
- DOI: https://dx.doi.org/10.3748/wjg.v22.i40.8967